Interventions of Interest:

  • donanemab (Eli Lilly & Co.)
  • lecanemab (Eisai Co., Ltd)
  • aducanumab (Aduhelm™, Biogen)

For questions, please contact Kelsey Gosselin, Program Manager, at

View the Key Stakeholder List.

Alzheimer’s disease (AD) is a fatal degenerative brain disease characterized by progressive loss of memory, cognitive skills such as language and problem-solving, and physical function. It is the most common cause of dementia in the United States (US), affecting an estimated 6.2 million Americans, and is the 6th leading cause of death.